SEC Tracker
Get the app

Aspira Women's Health AWHL

Aspira Women's Health Q1 FY26: revenue $32K; diluted EPS −$0.05

Form
10-Q
Filed
Period
Importance
Notable

Key figures from this report

These are the numbers Aspira Women's Health reported for Q1 FY26, the quarter ended Mar 31, 2026, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Revenue$32KAgainst $0 in Q1 FY2510-Q income statement, on EDGAR
  2. Net income$676KAgainst −$1.9M in Q1 FY2510-Q income statement, on EDGAR
  3. Diluted EPS−$0.05Against −$0.09 in Q1 FY2510-Q income statement, on EDGAR
  4. Cash and cash equivalents$1.3M−59% from $3.3M in Q1 FY2510-Q balance sheet, on EDGAR
  5. Cash from operations−$359KAgainst −$3.1M in Q1 FY2510-Q cash flow statement, on EDGAR

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Aspira Women's Health files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2835 and related industry codes: the same peer list as the financial tables.

  1. Creative Medical Technology Holdings CELZ public float $5M, Jun 30, 2025
  2. Target Group CBDY public float $5M, Jun 30, 2025
  3. Soligenix SNGX public float $5M, Jun 30, 2025
  4. Matinas BioPharma Holdings MTNB public float $5M, Jun 30, 2025
  5. Viskase Holdings ENZN public float $5M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.